Skip survey header

Antiplatelet Considerations in Cardiogenic Shock: A Case-based Review

  • To receive a CME certificate or certificate of participation, you must complete the evaluation first.
  • If you are on a mobile device, swipe left or use the arrow at the bottom of the screen to advance.
  • The Society for Cardiovascular Angiography and Interventions designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • * Denotes required field
Upon completion of this activity, participants will be able to:
  • Discuss the pharmacokinetic/pharmacodynamic profile of intravenous antiplatelets.
  • Review current data on antiplatelet needs of patients with cardiogenic shock and ACS.
  • Describe team-based strategies to properly manage antiplatelet therapy in STEMI and cardiogenic shock patients.

Rate how well the meeting met its educational objectives.  
*This question is required.
Space Cell Strongly AgreeAgreeNeutralDisagreeStrongly Disagree
The objectives of this educational activity were met.
I was satisfied with the overall quality of this educational activity.
This activity presented scientifically rigorous and balanced information.
2. Was the activity free of commercial bias?